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Reward modulation of cognitive function in adult
attention-deficit/hyperactivity disorder: a pilot study on the
role of striatal dopamine
Esther Aartsa,*, Mieke van Holsteina,*, Martine Hoogmanb,c, Marten Onninkc,
Cornelis Kanb, Barbara Frankeb,c, Jan Buitelaara,d,e and Roshan Coolsa,b
Attention-deficit/hyperactivity disorder (ADHD) is
accompanied by impairments in cognitive control, such as
task-switching deficits. We investigated whether such
problems, and their remediation by medication, reflect
abnormal reward motivation and associated striatal
dopamine transmission in ADHD. We used functional
genetic neuroimaging to assess the effects of dopaminergic
medication and reward motivation on task-switching and
striatal BOLD signal in 23 adults with ADHD, ON and OFF
methylphenidate, and 26 healthy controls. Critically, we took
into account interindividual variability in striatal dopamine
by exploiting a common genetic polymorphism (3′-UTR
VNTR) in the DAT1 gene coding for the dopamine
transporter. The results showed a highly significant group
by genotype interaction in the striatum. This was because a
subgroup of patients with ADHD showed markedly
exaggerated effects of reward on the striatal BOLD signal
during task-switching when they were OFF their
dopaminergic medication. Specifically, patients carrying the
9R allele showed a greater striatal signal than healthy
controls carrying this allele, whereas no effect of diagnosis
was observed in 10R homozygotes. Aberrant striatal
responses were normalized when 9R-carrying patients with
ADHD were ON medication. These pilot data indicate an
important role for aberrant reward motivation, striatal
dopamine and interindividual genetic differences in
cognitive processes in adult ADHD. Behavioural
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Kluwer Health, Inc. All rights reserved.
Behavioural Pharmacology 2015, 26:227–240
Keywords: attention-deficit/hyperactivity disorder, cognition, DAT1 genotype,
dopamine, functional magnetic resonance imaging, human, methylphenidate,
reward, striatum, task-switching
aCentre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and
Behaviour, Radboud University Nijmegen, bDepartment of Psychiatry,
cDepartment of Human Genetics, dDepartment of Cognitive Neuroscience,
Centre for Neuroscience, Radboud University Medical Center, Donders Institute
for Brain, Cognition and Behaviour and eKarakter Child and Adolescent Psychiatry
University Centre, Nijmegen, The Netherlands
Correspondence to Mieke van Holstein, MSc, Centre for Cognitive Neuroimaging,
Donders Institute for Brain, Cognition and Behaviour, Radboud University
Nijmegen, PO Box 9101, 6500 HB Nijmegen, The Netherlands
E-mail: miekevanholstein@gmail.com
*Esther Aarts and Mieke van Holstein contributed equally to the writing of this
article.
Received 23 July 2014 Accepted as revised 21 October 2014
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is
characterized by symptoms of inattention, impulsivity
and/or hyperactivity (American Psychiatric Association,
1994, 2013). Although originally considered a childhood
disorder, ADHD persists into adulthood in many cases,
and affects between 2.5 and 4.9% of the adult population
(Kooij et al., 2005; Kessler et al., 2006; Polanczyk et al.,
2007; Simon et al., 2009). A first-line treatment option for
ADHD is prescription of psychostimulant medication,
primarily the dopamine and noradrenaline transporter
blocker methylphenidate.
ADHD is associated with a wide range of cognitive
control deficits that span the domains of attention,
response inhibition, working memory and task-switching
(Barkley, 1997; Bush et al., 1999). Such cognitive control
deficits have been attributed most commonly (albeit not
exclusively; see Cortese et al., 2012) to (dorsal) prefrontal
cortex dysfunction (Dickstein et al., 2006; Cubillo et al.,
2010; Dibbets et al., 2010; McCarthy et al., 2014).
Accordingly, effects of methylphenidate on cognitive
control deficits in ADHD are considered to reflect action
(i.e. increasing synaptic levels of dopamine and nora-
drenaline) in the prefrontal cortex (Aron et al., 2003;
Berridge et al., 2006; Schmeichel et al., 2013; for a review,
see Arnsten and Li, 2005). In addition to cognitive con-
trol deficits, ADHD is accompanied by processing defi-
cits in the domains of reward and motivation (Sergeant
et al., 2003; Sonuga-Barke, 2003; Scheres et al., 2007;
Furukawa et al., 2014). Unlike the cognitive control
deficits, these reward-related deficits are often attributed
to changes in the ventral striatum (Ströhle et al., 2008;
Plichta et al., 2009; Hoogman et al., 2011, 2013; Carmona
et al., 2012; Volkow et al., 2012; Plichta and Scheres,
2014), as is the modulation of reward-related processing
by methylphenidate (Dodds et al., 2008). Indeed, besides
acting on noradrenaline transporters, methylphenidate
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acts by blocking dopamine transporters (DAT), which are
more abundant in the striatum than in the prefrontal
cortex (Volkow et al., 1995; Ciliax et al., 1999).
The observation that both cognitive control deficits and
reward-related deficits contribute towards ADHD con-
curs with the dual pathway model of ADHD, according
to which two subtypes of ADHD exist with different
developmental pathways, underpinned by different
neural circuits and modulated by different branches of
the dopamine system (Sonuga-Barke, 2002, 2003, 2005;
for more recent models, see Durston et al., 2011; de
Zeeuw et al., 2012). More specifically, disturbances in the
executive mesocortical dopamine circuit, encompassing
the dorsal striatum, dorsomedial thalamus and dorso-
lateral prefrontal cortex, underlie cognitive deficits in
ADHD, whereas motivational deficits are grounded in
disturbances in the mesolimbic reward circuit, including
the ventral striatum and the orbitofrontal cortex. Here, we
approach the issue from a different angle by asking whe-
ther cognitive task-related processing deficits and their
remediation by methylphenidate reflect indirect modula-
tion of motivation and reward-related processing in the
striatum rather than direct modulation of prefrontal pro-
cessing. This question is grounded in current neuroanato-
mical and neurochemical models that emphasize a
hierarchical arrangement of spiralling striatonigrostriatal
loops, allowing directional interaction between motiva-
tional and cognitive circuits (Haber et al., 2000; Haber,
2003; Ikeda et al., 2013). Furthermore, it concurs generally
with a large body of work showing that striatal dopamine is
important not just for motor control but also for cognitive
functioning (e.g. Cools et al., 1984). It also follows directly
from work showing that methylphenidate-induced changes
in striatal dopamine release can contribute towards cogni-
tive (attentional) symptoms in ADHD (Glow and Glow,
1979; Volkow et al., 2012). The hypothesis also concurs
with observations that cognitive deficits in children with
ADHD can be remediated by increases in motivation
(Konrad et al., 2000; Slusarek et al., 2001; Uebel et al., 2010),
although inconsistent findings have also been reported
(Oosterlaan and Sergeant, 1998; Desman et al., 2008;
Shanahan et al., 2008; Karalunas and Huang-Pollock, 2011).
None of these studies, however, speak to the neural
mechanisms of such motivational effects and their mod-
ulation by methylphenidate.
Here, we aimed to assess whether cognitive task-related
processing deficits in adult ADHD can be a function of
reward-related striatal functioning using functional MRI
(fMRI). To index reward effects on cognitive task-related
processing, we used a rewarded task-switching paradigm
that we established previously to be particularly sensitive
to changes in striatal dopamine transmission (Aarts et al.,
2010, 2011, 2012, 2014a, 2014b).
One major challenge for studies aiming to isolate dopa-
minergic drug effects is that such dopaminergic drug
effects vary considerably across different individuals as a
function of (genetically determined) baseline levels of
dopamine (Verheij and Cools, 2008; Cools and
D'Esposito, 2011; van Holstein et al., 2011). Previous
work suggests the possibility that the effects of methyl-
phenidate emerge only when taking into account such
interindividual differences (Clatworthy et al., 2009), for
example by exploiting known common polymorphisms
in dopamine genes. Here, we stratified our sample by
interindividual variation in the 40-bp variable number of
tandem repeats (VNTR) polymorphism in the 3′
untranslated region (3′-UTR) of the DAT gene (DAT1,
SLC6A3). This is based on several lines of evidence,
suggesting an important role for the DAT in the patho-
physiology of ADHD. The DAT is the main mechanism
responsible for clearing extracellular dopamine in the
striatum. Thus, genetic variation of the DAT1 gene might
lead to interindividual variation in the availability of
DATs and subsequently in dopamine levels. Although it
has remained inconclusive in the literature as to which
allele leads to decreased DAT availability (Costa et al.,
2011; Faraone et al., 2014), genetic fMRI studies have
consistently shown the 9-repeat (9R) allele to be asso-
ciated with increased striatal reward responses (Dreher
et al., 2009; Forbes et al., 2009; Aarts et al., 2010).
Furthermore, methylphenidate exerts its action in the
striatum by blocking the DAT (Volkow et al., 1998,
2002); mice that lack the DAT (i.e. DAT1 knockout
mice) show ADHD-like behaviour (Giros et al., 1996;
Gainetdinov et al., 1999), and several dopaminergic
genes, including the DAT1 genotype, have been impli-
cated in ADHD (Faraone et al., 2005; Brookes et al., 2008;
Franke et al., 2008; for a review, see Durston et al., 2009;
Gizer et al., 2009; Franke et al., 2010).
In summary, in this pilot study, we tested the hypothesis
that the effects of reward motivation on task-switching
and striatal BOLD signal vary as a function of the DAT1
genotype in adult patients with ADHD, when they were
OFF relative to ON their methylphenidate regimen,
compared with healthy controls.
Methods
Participants
We present data from 23 patients with ADHD
(mean ±SE age 35.74 ± 2.36; 14 men) and 26 healthy
control participants (mean ±SE age 38.08 ± 2.00; 11 men).
Patients visited our centre on two occasions: once after
intake of methylphenidate and once after withdrawal
from methylphenidate. Healthy controls were also tested
on two occasions, without any methylphenidate (see the
Procedure section).
Initially, we recruited 57 participants (29 patients with
ADHD and 28 healthy controls) from an ongoing study on
ADHD and genetics, IMpACT-NL (Hoogman et al., 2011,
2013; Onnink et al., 2014; http://www.impactADHDgenomics.
com), in which they were tested extensively, genotyped
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and diagnosed (Table 1). Patients were included if they
fulfilled the DSM-IV-TR criteria for ADHD in childhood
as well as adulthood. All participants were assessed using
the Diagnostic Interview for Adult ADHD (Kooij and
Francken, 2007). The Structured Clinical Interviews for
DSM-IV (SCID-I and SCID-II) were administered.
Assessments were carried out by trained professionals
(psychiatrists or psychologists). In addition, a quantitative
measure of clinical symptoms was obtained using the
ADHD rating scale-IV (Kooij et al., 2005). Exclusion cri-
teria for participants were alcohol or substance addiction in
the last 6 months, current psychosis, manic episodes,
obsessive–compulsive disorder or eating disorders (asses-
sed using SCID-I), full-scale IQ estimate less than 70
(assessed using the Wechsler Adult Intelligence Scale-III),
neurological disorders, sensorimotor disabilities and non-
Caucasian ethnicity. An additional exclusion criterion for
healthy comparison participants was a current or a past
neurological or psychiatric disorder according to SCID-I.
Three patients did not complete the testing sessions.
Two patients were excluded because they did not follow
instructions on methylphenidate withdrawal and/or
intake (see the Procedure section) and one because of
excessive head movement. One healthy control partici-
pant was excluded from analysis because of the sub-
optimal quality of the structural data, leading to
normalization difficulties, and one for fulfilling the cri-
teria for an ADHD diagnosis according to the ADHD
rating scale-IV (Kooij et al., 2005) (see the
Neuropsychological assessment section). Hence, 23
patients with ADHD and 26 healthy controls were
included in the final analyses.
All patients had a current prescription of methylpheni-
date [either immediate-release (Ritalin; N= 5; mean ±SD
44 ± 22.74 mg/day), or sustained release (Concerta;
N= 18; mean ± SD 48.5 ± 21.19 mg/day), and three of
them occasionally took Ritalin in addition to Concerta].
All participants were native speakers of Dutch.
Participants were compensated for participation and
provided written informed consent in a manner approved
by the local ethics committee on research involving
human participants (CMO Arnhem-Nijmegen 2009/058,
NL27180.091.09).
Procedure
All participants were asked to abstain from alcohol on the
day of testing and from nicotine and caffeine at least 1 h
before arriving at the centre. The patients were tested
once OFF (i.e. withdrawn from Ritalin for 24 h and from
Concerta for 48 h before testing) and once ON methyl-
phenidate [i.e. after intake of (mean ±SD) 13.15 ±
5.55 mg of Ritalin, the equivalent of (mean ±SD)
0.16 ± 0.05 mg/kg body weight of Ritalin, half an hour
before arriving at the centre]. Patients using sustained-
release methylphenidate were prescribed an equivalent
dose [instant dose (mg)= sustained dose (mg)× 0.278] of
immediate-release methylphenidate by the psychiatrist
(J.B.) for 1 day (three doses a day). Three patients using
additional medication (one antihistamine and two SSRIs)
were asked to take the same dose on both sessions. The
order of the ON and OFF session was approximately
counterbalanced across participants (Table 2). The
healthy control group did not take methylphenidate, but
was nevertheless tested twice to rule out order effects.
Control data were averaged across the two sessions.
Table 1 Demographics, impulsivity and diagnostic interview for diagnosis×DAT1 group
ADHD (N=23) HC (N=26) Univariate GLM/χ2/Fisher’s exact test
9R carriers 10R/10R 9R carriers 10R/10R ADHD vs. HC
9R carriers vs.
10R/10R Diagnosis×DAT1
Demographics
N 12 11 10 16 NS
Age [mean (SE)]b 36.25 (3.78) 35.18 (2.91) 41.1 (2.79) 36.25 (2.70) F(1,45)<1 F(1,45)<1 F(1,45)<1
IQ (WAIS III) [mean (SE)]a,b 11.58 (0.66) 12.72 (0.54) 12 (0.91) 12.31 (0.80) F(1,45)<1 F(1,45)=1.05; P>0.1 F(1,45)<1
Sex: males (N/%)c 7/58 7/64 4/40 7/44 P>0.1 P>0.1 P>0.1
Education level [mean (SE)]a,d 4.75 (0.22) 5.00 (0.30) 5.10 (0.23) 5.00 (0.26) χ2 (3)=1.77; P>0.1 χ2 (3)=5.03; P>0.1 χ2 (1)<1
Handedness: right handed (N/%)a,d 12/100 9/82 8/80 15/94 χ2 (2)=2.25; P>0.1 χ2 (2)<1 χ2 (1)<1
Smokers (N/%)c 6/50 6/55 3/30 5/31 P>0.1 P>0.1 P>0.1
BIS-11 impulsivity scoreb 74.75 (2.74) 71.09 (4.58) 58.9 (3.00) 59.5 (1.75) F(1,45)=20.78; P<0.001 F<1 F<1
SCID-Axis I current comorbiditiesa χ2: Fisher’s exact test
Depressive 0/10 1/11 0/9 0/15 NS NS NS
Dysthymic 0/10 1/11 0/9 0/15 NS NS NS
Anxiety 1/10 1/11 0/9 0/15 NS NS NS
SCID-Axis II Personalitya
Borderline 2/10 0/10 0/9 0/15 NS NS NS
Antisocial 1/10 0/10 0/9 0/15 NS NS NS
Obsessive–compulsive 2/10 0/10 0/9 0/15 NS NS NS
ADHD, attention-deficit/hyperactivity disorder; GLM, general linear model; HC, healthy controls.
aAdministered during the IMpACT-NL study; values indicate the number of participants fulfilling the criterion/total number of participants in which the SCID-I or SCID-II
was administered; 10R/10R=10R homozygotes.
bUnivariate GLM.
cχ2: Fisher’s exact test.
dχ2-test.
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Sessions were separated by at least 1 week and both
sessions took place at approximately the same time of
day. With the exception of medication state, the proce-
dure was identical for both groups and both sessions.
Cognitive task with reward manipulation
Participants were scanned while performing an estab-
lished precued task-switching paradigm (Fig. 1) with a
reward manipulation (Aarts et al., 2010, 2012, 2014a; van
Holstein et al., 2011). The paradigm started ∼ 60 min
after arrival (mean ± SD 91.8 ± 16.1 min after drug intake).
The task was programmed and presented using the
Presentation (R) software (Version 13, www.neurobs.com).
Participants had to respond to incongruent arrow–word
combinations, either by responding to the direction of the
arrow or the direction indicated by the word (‘left’ or
‘right’). A task-cue appeared 400 ms before the target
indicating the task (arrow or word) that the participant
had to perform on the current trial. Relative to the pre-
vious trial, the task either changed unpredictably (from
arrow to word or vice versa; switch trial) or remained the
same (repeat trial). The critical measure of interest, the
switch cost, was calculated by subtracting performance on
repeat trials from that on switch trials. In addition, we
manipulated reward motivation, to assess the effect of
reward on task-switching, by presenting high and low
reward cues before the task cue. The reward-cue
informed the participants whether 1 cent (low reward) or
15 cents (high reward) could be earned with a correct and
sufficiently quick response. Immediately after the
response, feedback was provided (e.g. ‘correct! 15 cents’).
There was a variable interval of 2–6s between the reward-
cue and the task-cues. Participants used their right index
and middle fingers to respond on a button box.
On both sessions, the task was practiced twice outside
the scanner and once inside the scanner. The first prac-
tice block contained 24 trials with the task cue, target and
feedback (correct/incorrect). As soon as participants suc-
ceeded in completing this block with less than five errors,
the second practice block of 24 trials was performed, in
which the reward cues were included. The third and final
practice block was performed during the acquisition of
the anatomical scan. The mean response times (RT) of
the correct trials per trial-type (arrow-repeat, arrow-
switch, word-repeat, word-switch trials) in this third
practice block were used as the response deadline in the
main experiment. This ensured equal difficulty across
participants and sessions.
The main experiment consisted of 160 trials and
lasted∼ 35 min with a 30 s break after every 32 trials. In
the break, the amount of money that the participant had
earned thus far was displayed on the screen and partici-
pants were told in advance that the total amount would
be added to their financial compensation as a bonus.
Neuropsychological assessment
During the first session, participants completed the
Barratt Impulsiveness Scale (BIS-11a; Patton et al., 1995),
a self-report trait measure of impulsivity. At the begin-
ning of both sessions, participants completed the Bond
and Lader (1974) visual analogue scale for a comparison
of mood between sessions (16 moods rated on a scale of
0–100, resulting in three mood categories) and an ADHD
symptom rating scale (Kooij et al., 2005) to assess self-
reported ADHD symptoms. Motor speed was measured
using the box completion task (Salthouse, 1996), sus-
tained attention with the digit vigilance or the number
cancellation task (Lewis and Kupke, 1977) and verbal
fluency with the begin letters D, A and T (Spreen and
Benton, 1977).
Genotyping
DNA was isolated from EDTA blood samples.
Genotyping of the 40-bp VNTR in the 3′-UTR of
SLC6A3/DAT1 was carried out as described previously
(Hoogman et al., 2013) at the department of Human
Genetics of the Radboud University Medical Centre. In
line with previous studies reporting the effect of this var-
iant, we established a group of carriers of the 9R allele (i.e.
the risk factor for adult ADHD) and a group homozygous
for the 10R allele (Colzato et al., 2010; Rokem et al., 2012)
(Table 1). We preselected our participants from a previous
sample (Hoogman et al., 2013) to homogenize sample
numbers per group (diagnosis× genotype) as much as
possible. Therefore, Hardy–Weinberg equilibrium was not
considered.
In the ADHD group, 12 individuals were carriers of the
9R allele and 11 individuals were homozygous for the
10R allele (Table 1). In the healthy control group, 10
individuals were carriers of the 9R allele and 16 indivi-
duals were homozygous for the 10R allele. We performed
a power calculation in G*Power (http://www.gpower.hhu.de)
on the basis of the effect sizes obtained in an indepen-
dent dataset using a similar rewarded task-switching
paradigm and the same VNTR in the DAT1 gene in
Table 2 Attention-deficit/hyperactivity disorder characteristics
ADHD Statistics
9R carriers 10R/10R DAT1 effect
First session ON MPH 6/50% 6/55% NS
Ritalin dose ON [mean (SE)] 14.38 (1.80) 11.82 (1.39) NS
Ritalina 1/9% 4/33% NS
Concerta dose [mean (SE)] 53.18 (6.91) 36.63 (7.20) NS
Subtypes: DIVAb NS
Combined 11 6
Inattentive 0 3
Hyperactive/impulsive 0 1
ADHD, attention-deficit/hyperactivity disorder; MPH, methylphenidate; 10R/10R,
10R homozygotes.
aThree of the Concerta users (one 9R carrier) occasionally took 15mg Ritalin in
addition to Concerta.
bDIVA was not administered for one patient in each DAT1 group.
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healthy volunteers (Aarts et al., 2010). The power calcu-
lation showed that we would need at least eight partici-
pants per group (four groups: genotype× diagnosis) to
obtain significant effects of genotype on striatal BOLD
responses during the rewarded task-switching [effect
size= 0.78; α= 0.05; power (1− β)= 0.8]. Currently, our
smallest group includes 10 participants.
Functional magnetic resonance imaging data acquisition
Participants were scanned in a 3TMR scanner (Magnetom
TrioTim; Siemens Medical Systems, Erlangen, Germany)
using an eight-channel head coil. T2*-weighted images
were acquired with a gradient echo planar imaging (EPI)
sequence (30 axial slices, repetition time= 2020ms, echo
time= 30ms, voxel size= 3.5× 3.5× 3mm, field of
view= 224mm, flip angle= 80°). All functional images
were acquired in a single run. Stimuli were presented on a
computer display projected onto a mirror attached to the
head coil. The first four volumes were discarded to allow
for T1 equilibrium. Before the acquisition of the functional
images, a high-resolution T1-weighted MP-RAGE anato-
mical scan was obtained (192 sagittal slices, repetition
time= 2300ms, echo time= 3.03ms, voxel size= 1×1× 1
mm, field of view=256mm).
Functional magnetic resonance imaging statistical
analyses
Data were preprocessed and analysed using SPM5
(Wellcome Department of Cognitive Neurology,
London, UK). First, functional EPI images were spatially
realigned and corrected for differences in slice acquisition
timing. Structural and functional data were co-registered
and normalized to a standard anatomical space (Montreal
Neurological Institute) using a unified segmentation
procedure (Ashburner and Friston, 2005). The normal-
ized images were smoothed with an isotropic 8-mm full-
width-at-half-maximum Gaussian kernel.
The preprocessed fMRI time series were analysed at the
first level using an event-related approach in the context
of the general linear model (GLM). Our statistical model
on the first (participant-specific) level considered the
factors reward (high, low), task (arrow, word), task-
switching (repeat, switch) and feedback (correct-1 cent,
correct-15 cents, error-0 cents, too late-0 cents). This
resulted in 21 regressors of interest: two regressors for
reward-cues, eight regressors for targets (reward× task×
task-switching) and four regressors for feedback. All
regressors of interest were modelled as a stick function
(duration= 0) convolved with a canonical haemodynamic
response function. In addition, breaks (duration of 30 s),
six motion parameters and their derivatives were mod-
elled as regressors of noninterest. Finally, we included
three regressors of noninterest to account for movement-
induced intensity changes using the mean time series
from the segmented white matter, cerebral spinal fluid
and out-of-brain signals (Majdandzić et al., 2007;
Verhagen et al., 2008). High-pass filtering (128 s) was
applied to the time series of the functional images to
remove low-frequency drifts.
Fig. 1
Trial 1
(discarded)
Correct!
15 cents
Correct!
1 cent
Correct!
1 cent
Correct!
15 cents
Incorrect!
0 cent
Incorrect!
0 cent
Incorrect!
0 cent
Incorrect!
0 cent
Trial 2
(low reward, task switch)
Trial 3
(low reward, task repeat)
Trial 4
(high reward, task switch)
Reward cue
Task cue
Target
Feedback
Right buttonRight buttonRight buttonRight button Left buttonLeft buttonLeft buttonLeft button
15 cents 1cent 1cent
ArrowArrow
15 cents
WordWord
Left LeftRight Left
Task-switching paradigm with reward manipulation. Participants were instructed to respond either to the direction indicated by the arrow (i.e.← or→)
or to the direction indicated by the word (i.e. ‘left’ or ‘right’) with a left or a right button press. The task performed on a particular trial either changed
compared with the preceding trial (i.e. switch trial; arrow–word or word–arrow) or remained the same (i.e. repeat trial; arrow–arrow, word–word). In
addition, we manipulated the amount of anticipated reward (e.g. 1 vs. 15 cents) on a trial-by-trial basis by means of a reward anticipation cue. At the
start of each trial, this cue indicated the amount of reward on that trial, providing a correct and sufficiently fast button press (see also Aarts et al.,
2010).
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At the second level, the reward× task-switching contrast
images from the first level were used in three GLMs to
assess the effects of reward during task-switching: two
models to assess the interaction with the DAT1 genotype
and diagnosis (HC vs. ADHD OFF and ADHD ON vs.
HC) and one model to test the interaction with the DAT1
genotype and medication (ADHD ON vs. ADHD OFF).
Statistical inference (P< 0.05) was performed at the
cluster level, correcting for multiple comparisons over the
search volume (the whole brain). The intensity threshold
necessary to determine the cluster-level threshold was
set at P less than 0.001, uncorrected. For each effect, we
report the t-values at the voxel level, the whole-brain
corrected P-values for the cluster (Pcluster) and the size of
the cluster (k). In addition, supplementary exploratory
analyses were carried out, for which the uncorrected
threshold was set to P less than 0.001, and we report the
t-values and P-values (Puncorr) at the voxel level.
Behavioural statistical analyses
We excluded the first trial of each block (five trials in
total) because these cannot be considered as either repeat
or switch trials. All trials to which participants responded
(i.e. all trials except response omissions) were included in
the analysis, even if the response was too late for a reward
to be obtained. For the analysis of the mean RTs, we
excluded responses faster than 200 ms. For each partici-
pant, we calculated the mean RTs for all the correct
responses and the proportion of errors for each of the four
conditions, that is reward (high–low)× switching (switch-
repeat). To maximize homogeneity of variances between
groups and to ensure normal distribution of the data, a
natural logarithm (LN) transformation was applied to the
mean RTs. The mean proportions of incorrect responses
were transformed using the following formula: 2× arcsin√x
(Sheskin 2004). Levene’s tests of homogeneity of variances
and Shapiro–Wilk tests of normality showed that this
transformation was successful in improving variance
between groups and the distribution of the data.
Proportions or errors and mean RTs were analysed using
a repeated-measures GLM with the within-participant
factors reward (high, low), switching (repeat, switch), the
between-participant factor DAT1 genotype (9R carriers,
10R homozygotes) and either the between-participant
factor diagnosis (ADHD or healthy control) or the within-
participant factor medication (ON, OFF). Effects were
considered significant when P-values were less than 0.05.
Statistical analysis of mood measures and
neuropsychological tests
Mood values were calculated for each session and reduced
to three factors: contentedness, alertness and calmness,
according to Bond and Lader (1974). Neuropsychological
and demographic differences between groups or medica-
tion states and their interaction with the DAT1 genotype
were tested using SPSS (IBM Corp. IBM SPSS Statistics
for Windows, Version 21.0. Armonk, New York, USA)
with univariate or repeated measures GLMs or their non
parametric counterparts (Wilcoxon signed rank or Mann–
Whitney U-tests, respectively; Table 3). Nonparametric
DAT1 genotype×medication interactions were assessed
using a Mann–Whitney U-test of the difference between
the score OFF and ON medication. Nonparametric DAT1
genotype×diagnosis effects were assessed using the
Kruskal–Wallis test (Table 3). An effect was considered
significant when P less than 0.05.
Results
Functional magnetic resonance imaging effects
Main task effects
Across groups and sessions, the cue indicating a high
reward, compared with the cue indicating a low reward,
elicited a robust response in regions in the striatum, the
frontal cortex and the occipital cortex (Table 4). There
was also a strong main effect of task-switching during the
targets, as evidenced by a greater response in the frontal
and parietal regions on switch compared with repeat trials
(Table 4).
ADHD OFF versus healthy controls
The BOLD signal in the dorsal striatum varied highly
significantly as a function of ADHD diagnosis (patients
with ADHD OFF their medication versus healthy con-
trols), DAT1 genotype (9R carriers vs. 10R homozygotes)
and task (reward× task-switching) (x, y, z=− 20, 4, 16;
t= 4.92; Pcluster< 0.001; k= 324; Fig. 2a-I). This finding
concurs with our hypothesis that the effect of reward on
task-switching in the striatum would vary as a function of
the DAT1 genotype and diagnosis (healthy controls
compared with patients with ADHD). The striatal effect
was observed because of a greater task-related signal in
patients with ADHD carrying the 9R allele compared with
9R carriers in the healthy control group (reward× task-
switching×diagnosis in 9R carriers: x, y, z=− 18, 2, 16;
t= 4.90; Pcluster= 0.001; k= 333) and greater task-related
signal in the 9R-carrying patients with ADHD compared
with the 10R homozygous patients with ADHD
(reward× task-switching×DAT1 in patients with ADHD
OFF medication: x, y, z=− 12, − 4, 6; t= 4.96;
Pcluster= 0.002; k= 295). To illustrate this effect, we
extracted the beta values from the cluster in the left dorsal
striatum shown in Fig. 2a-I and plotted the results in
Fig. 2b. The only other significant neural difference
between the ADHD group OFF medication and the
healthy control group was observed in the posterior cin-
gulate cortex (reward× task-switching×diagnosis×DAT1:
x, y, z=− 6, − 12, 46; t= 5.56; Pcluster< 0.001; k= 338).
ADHD ON versus healthy controls and ADHD OFF
versus ADHD ON
There was no longer an effect of diagnosis when com-
paring patients with ADHD ON medication with healthy
controls, suggesting that the aberrant striatal response
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was restored by medication. Although a direct compar-
ison of the ON and OFF session (ADHD ON vs. ADHD
OFF medication) did not reach significance at our strin-
gent threshold, exploratory analyses confirmed that task-
related responses in the same region in the striatum were
reduced for patients ON relative to OFF medication
depending on the DAT1 genotype (reward× task-
switching×DAT1×medication: x, y, z=− 20, 4, 16;
t= 3.63; Puncorr< 0.001; Fig. 2a-II and b). This is gen-
erally in line with the hypothesis that the effect of
methylphenidate and reward motivation on task-
switching would vary as a function of the DAT1 geno-
type and medication status (patients with ADHD ON
compared with OFF their medication).
Behavioural effects
Main task effects
Participants responded more quickly after a high than a
low reward (i.e. across groups, irrespective of diagnosis
and genotype), as evidenced by a main effect of
reward on RTs [F(1,48)= 24.36; P< 0.001]. Participants
also responded more quickly on repeat than switch
trials [main effect of task-switching: F(1,48)= 24.91;
P< 0.001]. In addition, participants made more errors on
switch than repeat trials [main effect of task-switching
F(1,48)= 28.67; P< 0.001; Table 5].
Attention-deficit/hyperactivity disorder OFF versus
healthy controls
There were no significant differences in RT between the
ADHD group OFF medication and healthy controls
(Fig. 2c). However, the groups did differ in terms of the
reward effect (i.e. low–high reward) on error rates, across
switch and repeat trials. This effect depended on the
DAT1 genotype [reward×diagnosis×DAT1: F(1,45)=5.56;
P=0.023]: irrespective of task-switching, the 10R homo-
zygotes in the ADHD group made fewer errors on high than
low reward trials, relative to the 10R homozygotes in the
healthy control group [reward×diagnosis in 10R homo-
zygotes: F(1,25)=7.03; P<0.02; Table 5], whereas there
was no difference between the 9R carriers in the ADHD
group and the healthy 9R group. The critical effect of
reward on task-switching errors did not differ between the
patients with ADHD OFF medication and the healthy
control group as a function of DAT1 genotype [the critical
reward× task-switching×diagnosis×DAT1 interaction: error
rates F(1,45)<1; RTs F(1,45)=1.92; P>0.1].
Attention-deficit/hyperactivity disorder ON versus
healthy controls
There were no significant differences in RT between the
ADHD group ON medication and healthy controls. Switch
costs in error rates were significantly greater in the ADHD
group ON medication than in the healthy control group
[task-switching×diagnosis: F(1,45)= 6.44; P< 0.02]. The
critical effect of reward on task-switching did not differ
between the patients with ADHD ONmedication and theTa
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healthy control group as a function of DAT1 genotype [the
critical interaction between reward× task-switching×
diagnosis×DAT1: error rates F(1,45)= 1.37; P> 0.1; RTs
F(1,45)< 1].
ADHD OFF versus ADHD ON
There was no significant difference between the two
medication sessions in RTs or error rates. The critical
DAT1 by medication by reward task-switching interaction
only trended towards significance for RTs [reward× task-
switching×medication×DAT1: F(1,21)= 3.23; P= 0.087;
Fig. 2c], and was absent for error rates [reward× task-
switching×medication×DAT1: F(1,21)< 1].
In summary, unlike the brain data, the behavioural data
did not show any significant effects of diagnosis or
medication status and/or genotype on how anticipated
reward influences task-switching performance (i.e.
reward× task-switching effects). To assess whether the
increased BOLD signal in the striatum of 9R-carrying
patients with ADHD was accompanied, if anything, by
behavioural impairment or improvement, we examined
the numerical (marginal trend) pattern in RTs (Fig. 2c).
Disentangling this marginally significant effect [reward×
task-switching×medication×DAT1: F(1,21)= 3.23;
P= 0.087] showed that 9R-carrying patients OFF medi-
cation tended to show a greater switch cost on high than
low reward trials compared with these patients ON their
medication [reward× task-switching×medication in 9R
carriers: F(1,11)= 4.40; P= 0.06; Fig. 2c]. These data
suggest that the increased dorsal striatal responses in
patients with ADHD carrying the 9R allele are accom-
panied, if anything, by a detrimental effect of reward on
task-switching that can be remediated by methylpheni-
date (Fig. 2b and c).
Demographic and neuropsychological data
Table 1 summarizes the demographic and neuropsycho-
logical data of the patients with ADHD and healthy
controls for the two DAT1 genotype groups. There was
no difference between patients and healthy controls, or
between the 9R-carrying and 10R homozygous group, in
terms of age, IQ, sex, handedness, smoking status and
level of education (Table 1), nor an interaction between
diagnosis and the DAT1 genotype. As expected, the
patients with ADHD scored higher on the Barratt
Impulsiveness Scale (mean ± SE: 73.00 ± 2.58); that is,
they were more impulsive than the healthy controls
[mean ±SE: 59.27 ± 1.54; t (47)= 4.70; P< 0.001]. There
were no differences in current SCID Axis I disorders or
SCID Axis II personality traits as a function of diagnosis,
DAT1 genotype or diagnosis×DAT1 genotype.
Counterbalancing of the ON and OFF sessions within the
two DAT1 genotype patient groups was successful: there
was no difference between the two DAT1 groups in the
number of patients being ON medication during the first
session. Furthermore, there were no significant differences
in the dose of Ritalin or Concerta between the DAT1
genotype groups, nor in the number of patients usually
taking either form of methylphenidate, or in their ADHD
subtype (i.e. combined, inattentive or hyperactive/impul-
sive) (Table 2).
Table 3 summarizes the mood and neuropsychological
test scores. Most importantly, there were no interactions
between the DAT1 genotype and either medication state
Table 4 BOLD maxima across all participants
MNI coordinates
Label Brodmann
Side
(L/R) x y z
Cluster size
(number of voxels)
Significance
(cluster level)
t-value
(peak)
Main effect reward: high> low reward
Superior parietal lobe (B7)a 7 L −16 −68 56 3126 P<0.001 7.38
Insular cortex (B13)a extending into the striatum,
pallidum and thalamus
13 L+R 30 26 0 3468 P<0.001 6.56
Cingulate gyrus (B32)a 32 L+R −4 12 40 3171 P<0.001 6.24
Occipital lobe (B16)a 16 L −26 −94 12 352 P<0.002 5.81
Cingulate gyrus (B23)a 23 L+R −4 −30 28 283 P<0.005 5.43
Main effect reward: low> high reward
Inferior frontal gyrus 10 R 48 46 8 368 P<0.002 6.29
Posterior cingulate Precuneus 31 L+R −6 −56 20 460 P<0.001 4.76
Superior temporal gyrus 39 R 50 −60 26 248 P<0.01 4.42
Superior frontal gyrus 9 L 12 56 26 228 P<0.02 4.06
Main effect switch: switch> repeat
Precuneus (B7)a 7 L −24 −66 34 3289 P<0.001 6.89
Inferior frontal gyrus (B9)a 9 L −48 12 28 1675 P<0.001 6.02
Middle frontal gyrus (B11)a 11 L −24 48 −10 221 P<0.018 5.43
Main effect switch: repeat> switch
Superior Temporal gyus 41 R 56 −28 12 694 P<0.001 4.72
Occipital lobe (cuneus) 19 R 14 −88 34 180 P<0.04 3.94
Superior temporal gyrus 41 L −44 −32 14 617 P<0.001 3.90
Main effect of reward anticipation during cues and main effect of task-switching during targets at a whole-brain cluster-level corrected threshold of P<0.05.
aAlso significant after FWE correction at the voxel level (PFWE<0.05).
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Brain activation: ADHD OFF vs. ADHD ON
Values
(a-I)
(b)
(c)
(a-II)
P< 0.001 (t > 3.28) cluster-level corrected
P< 0.005 (t > 2.69) uncorrected
Values
P< 0.001 (t > 3.29) uncorrected
P< 0.005 (t > 2.69) uncorrected
Rewarded task-switching as a function of the DAT1 genotype in patients with attention-deficit/hyperactivity disorder (ADHD) ON and OFF their
methylphenidate medication, relative to healthy controls (HC). (a-I) Increased dorsal striatal responses during rewarded task-switching for patients
with ADHD OFF methylphenidate relative to healthy controls, as a function of the DAT1 genotype; (a-II) Increased dorsal striatal responses during
rewarded task-switching for patients with ADHD OFF methylphenidate relative to when ON methylphenidate, as a function of the DAT1 genotype; (b)
The β values from the whole-brain cluster-corrected cluster in the left striatum depicted in (a-I), showing the direction of the effect; (c) The response
times during rewarded task-switching. Positive values reflect an increased switch cost (i.e. slower on switch than on repeat trials) for high reward
relative to low reward trials, that is a detrimental effect of reward on the switch cost. Error bars represent the SE of the difference between high
reward (switch-repeat) minus low reward (switch-repeat).
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(ON or OFF) or diagnosis on mood measures or on the
neuropsychological test scores. However, patients OFF
medication were reportedly less content and less alert
than healthy controls, and compared with when they
were ON medication (Table 3; contentedness: ADHD
ON median 83, range 41.6–95.2; ADHD OFF median
67.16, range 23.2–97.6). In addition, healthy controls
reported more calmness than the patients, both ON and
OFF medication (Table 3). There were no differences in
motor speed (box completion task) on the time to com-
plete the vigilance test (number cancellation RT) or in
verbal fluency. We did observe a difference between the
ADHD group OFF medication and the healthy control
group for missed items on the vigilance test, that is the
ADHD group OFF their medication missed more num-
bers (median 4, range 0–17) relative to the healthy control
group (median 2, range 0–11) and relative to when ON
medication (median 3, range 0–13). This difference was
no longer present when comparing the ADHD group ON
medication with the healthy control group (Table 3).
As expected, methylphenidate ameliorated symptom
severity (Table 6) both on attentive and on hyperactive
symptoms. We did not observe effects of the DAT1
genotype, nor an interaction between the DAT1 genotype
and medication status on symptom severity (Table 6).
Discussion
We investigated the effects of reward motivation on task-
switching in adult patients with ADHD, ON and OFF
methylphenidate, relative to a matching healthy control
group. Task-related BOLD responses were assessed as a
function of interindividual variability in the DAT1 gene.
When OFF medication, adults with ADHD showed
greater effects of reward on dorsal striatal BOLD
responses during task-switching than healthy controls.
Critically, this effect was only observed when taking the
DAT1 genotype into account, resulting in a strong
genotype-by-diagnosis interaction. Specifically, patients
carrying the 9R allele showed exaggerated striatal
responses relative to healthy controls carrying the same
allele as well as relative to patients homozygous for the
10R allele. These aberrant striatal responses were nor-
malized when patients with ADHD were ON medica-
tion, such that they no longer differed from those of
controls. In short, the present pilot study shows a dys-
functional influence of reward motivation on task-
switching in the dorsal striatum of adult patients with
ADHD, but only in those carrying the 9R risk allele.
These findings, albeit preliminary because of the small
sample size, suggest that abnormal cognitive task-related
processing in adult ADHD depends critically on inter-
individual trait differences in striatal dopamine trans-
mission as well as on the motivational state of the
individual patient.
The present results indicate the importance of taking
into account interindividual variability, as for example
indexed by the DAT1 genotype, when assessing task-
related BOLD effects in ADHD. This generally concurs
with previous fMRI studies in youth with ADHD, which
have found that striatal responses during reward antici-
pation (Paloyelis et al., 2012), as well as striatal responses
during more cognitive tasks, that is Go/No-Go paradigms
Table 5 Means (SE) for response times and error rates (% errors)
Mean response times (SE) (ms) Error rates (SE) (%)
9R carriers 10R homozygotes 9R carriers 10R homozygotes
Repeat Switch Repeat Switch Repeat Switch Repeat Switch
HC
Low 411.36 (8.44) 421.48 (10.70) 406.81 (19.05) 413.57 (21.14) 2.68 (0.62) 3.19 (0.72) 1.67 (0.34) 2.44 (0.45)
High 402.51 (8.23) 416.24 (10.68) 397.51 (19.05) 405.75 (20.62) 2.55 (0.49) 2.36 (0.43) 1.65 (0.39) 2.82 (0.45)
ADHD OFF
Low 426.90 (21.15) 431.03 (24.37) 409.45 (24.13) 427.54 (29.15) 3.39 (0.58) 4.84 (0.94) 2.36 (0.33) 3.76 (0.67)
High 421.97 (20.68) 442.20 (21.51) 404.46 (23.52) 413.80 (25.62) 3.44 (0.64) 5.16 (0.88) 1.83 (0.62) 3.42 (0.68)
ADHD ON
Low 417.99 (26.71) 424.03 (27.82) 395.13 (19.94) 405.49 (21.80) 3.17 (0.61) 3.98 (0.77) 1.59 (0.35) 3.28 (0.42)
High 415.29 (27.24) 413.85 (27.25) 387.27 (18.22) 391.64 (21.66) 2.85 (0.70) 3.98 (0.79) 1.53 (0.45) 3.23 (0.55)
Data are shown for the attention-deficit/hyperactivity disorder (ADHD) group for each medication state (ON or OFF methylphenidate) and by the DAT1 genotype group
(9R+ or 10R homozygotes) for both the ADHD and the healthy control group (HC).
Table 6 Self-reported symptom severity
ADHD ON ADHD OFF Statistics
9R carriers 10R/10R 9R carriers 10R/10R Drug effect DAT1 effect Drug×DAT1
Symptom severity
Attentive [mean (SE)] 2.67 (0.66) 3.18 (1.11) 7.25 (0.46) 5.64 (0.83) t(22)=5.92; P<0.001 NS F(1,21)=3.47; P>0.05
Hyperactive [mean (SE)] 2.67 (0.66) 2.36 (0.75) 5.33 (0.68) 5.09 (0.72) t(22)=5.15; P<0.001 NS NS
ADHD, attention-deficit/hyperactivity disorder; 10R/10R, 10R homozygotes.
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(Durston et al., 2008; Bédard et al., 2010), depend on
variations in the DAT1 genotype. A recent study in adults
with ADHD failed to extend the effect of the DAT1
genotype on striatal reward responses during reward
anticipation, observed in youth (Paloyelis et al., 2012), to
adult ADHD (Hoogman et al., 2013). In the current
sample with ADHD adults, DAT1 effects on reward-
related striatal responses did emerge, but only as a
function of cognitive task-related processing. This sug-
gests that, in adults with ADHD, the translation of
reward information into (effortful) cognitive processing
might be more strongly dependent on variability in the
DAT1 gene than reward anticipation itself.
Our study shows that patients with ADHD OFF medi-
cation show abnormal BOLD responses in the caudate
nucleus during rewarded task-switching, an effect that
relied on striatal dopamine signalling as indexed by the
DAT1 genotype. In accordance, the caudate nucleus –
known to be involved in cognitive flexibility (Cools,
1980; Aarts et al., 2011) – is well positioned to incorporate
motivational influences from more ventral regions in the
striatum through feed-forward dopaminergic projections
(Haber et al., 2000; Grahn et al., 2008; Ikeda et al., 2013).
The finding is also remarkably consistent with our pre-
vious work using genetic fMRI and PET imaging in
healthy volunteers, showing that the effects of reward
motivation on cognitive control are altered by dopami-
nergic transmission in the left caudate nucleus (Aarts
et al., 2010, 2014b). In ADHD, Volkow et al. (2009) have
shown that dopaminergic transmission in reward-related
brain regions is associated with symptoms of inattention,
and that connectivity between neural reward and atten-
tion networks is impaired (Tomasi and Volkow, 2012).
Here, we show that cognitive task-related processing
deficits in the striatum (i.e. during task-switching) are
modulated by motivation as well as the DAT1 genotype
in ADHD. Unlike earlier suggestions (Sonuga-Barke,
2002, 2003; de Zeeuw et al., 2012), ADHD might not be
accompanied by isolated deficits in either motivational or
cognitive/executive processing pathways, but rather by
deficits in the integration between these pathways.
The present finding extends to ADHD our previous
work in young healthy volunteers showing that the
effects of reward motivation on task-switching and asso-
ciated striatal signal depend on the DAT1 genotype (Aarts
et al., 2010; see also van Holstein et al., 2011). Unlike that
previous study, however, the present study did not show
any DAT1 genotype effects on rewarded task-switching
in healthy controls, in neural or behavioural terms. We
are surprised at this lack of effect, but believe that it
might reflect a difference in the demographics between
the current control group, which was matched to the
ADHD group, and the groups in our previous studies that
primarily included university students. The most obvious
difference is in terms of age, with the current control
group being older (mean 38.12 years, SD 10.20) than
the healthy volunteers in our previous studies (mean
21.58 years, SD 2.06; and mean 22 years, SD 2.32, for
Aarts et al., 2010; van Holstein et al., 2011, respectively).
Indeed, studies have consistently observed a reduction in
dopamine signalling starting in young adulthood (e.g.
Volkow et al., 1996; Reeves et al., 2002). Importantly, the
increases in striatal BOLD in the 9R-carrying patients
OFF medication were, if anything, accompanied by
impaired performance (i.e. increased RT switch cost for
high vs. low reward trials, relative to when ON medica-
tion). These results contrast with our findings in younger
9R-carrying healthy volunteers who showed increased
striatal responses as well as better task-switching perfor-
mance following high versus low reward cues relative to
10R-homozygotes (Aarts et al., 2010). This suggests that
the hyperactivation in the dorsal striatum during rewar-
ded task-switching in the 9R-carrying patients OFF
medication is maladaptive for behaviour. The notion of
maladaptive striatal hyperactivation in 9R-carrying
patients with ADHD is in line with the finding that the
9R allele is the risk allele in adult ADHD (Franke et al.,
2010). However, the absence of significant behavioural
differences relative to healthy controls precludes state-
ments of normality in terms of performance.
The aberrant striatal responses during rewarded task-
switching in patients with ADHD (specifically 9R car-
riers) relative to controls were absent when patients were
ON medication. This suggests that methylphenidate
normalized striatal responses, although we only obtained
trend effects (i.e. at P<0.001 uncorrected for multiple
comparisons) when directly comparing patients ON ver-
sus OFF methylphenidate. Our findings suggest that the
effects of methylphenidate on cognitive task-related
processing are accompanied by modulation of the stria-
tum. This generally concurs with previous work showing
that methylphenidate can normalize striatal responses
during cognitive processes such as response inhibition
(Vaidya et al., 1998; Shafritz et al., 2004; Epstein et al.,
2007; Rubia et al., 2009, 2011). Here, we show that such
normalization of task-related dorsal striatal responses and
performance by methylphenidate depends both on the
DAT1 genotype and on reward motivation. This suggests
that reward motivational factors interact with the effects
of the DAT1 genotype to bias the cognitive response
to methylphenidate. Future work should address the
obvious next question, that is, whether the discrepancy in
the extant literature on the effects of the DAT1 genotype
on the clinical response to medication (Kambeitz et al.,
2014) also reflects variability in the patient’s reward
motivational state. Cognitive neuroimaging measures of
task-related (motivational) processing might be particu-
larly sensitive to detecting DAT1-dependent effects of
methylphenidate in ADHD.
It might be noted that the effects in the OFF state could
reflect rebound effects because of short-term medication
withdrawal. Future studies, with a longitudinal design or
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comparing medication-naive patients with medicated
patients, will need to determine whether the current
findings reflect rebound or withdrawal effects rather than
an unmedicated ADHD state.
Our findings were obtained with a sample of 23 patients
with ADHD and 26 healthy controls. This limited sample
size calls for caution when generalizing to the population
(Munafò and Gage, 2013) and precludes definitive con-
clusions. The findings should therefore be considered
preliminary and in need of replication, as was recently
also explicitly highlighted (Button et al., 2013).
Nevertheless, we believe that our findings are robust,
given extensive convergent evidence. Indeed, we have
previously observed effects of the DAT1 genotype on the
BOLD signal during rewarded task-switching in the
same striatal region (i.e. left caudate nucleus) as we report
here (Aarts et al., 2010). Moreover, we have observed
previously that striatal dopamine synthesis capacity in the
(left) caudate nucleus predicted the effects of reward on
cognitive performance during a focused attention task
(Aarts et al., 2014b). It is unlikely that our whole-brain
corrected results represent a false-positive effect as our
power calculation based on an independent dataset (Aarts
et al., 2010; Button et al., 2013) confirmed that our sample
should be large enough to obtain significantly meaningful
effects (see the Methods section). Replication of the
effect in independent larger samples in future studies
will further increase confidence in the reliability of
the effect.
Previously, we have obtained similar results in a PET
study in healthy volunteers, showing that dopaminergic
transmission in the left caudate nucleus altered the
effects of reward motivation on cognitive control (Aarts
et al., 2014b). In that study, we used a Stroop interference
paradigm instead of a task-switching paradigm, suggest-
ing that our present results can be extended to other
domains of cognitive control. However, future work
should confirm whether our findings in ADHD can be
generalized to domains other than task-switching.
Moreover, future studies should also examine variation in
other dopaminergic genes, such as COMT (Bilder et al.,
2004), to investigate whether the current findings are
limited to striatal dopamine processing.
Conclusion
Our data suggest a dysfunctional influence of reward
motivation on cognitive processing (i.e. task-switching) in
the dorsal striatum of adult patients with ADHD, who
carry the 9R ADHD risk allele. This deficit is remediated
when patients are tested ON methylphenidate. These
findings indicate an important role for both reward
motivation and interindividual trait differences in striatal
dopamine transmission in cognitive processing deficits in
adult ADHD.
Acknowledgements
The authors thank Paul Gaalman for assistance during
the acquisition of the MRI data. This work was sup-
ported by a James McDonnell scholar award to R.C.
Conflicts of interest
E.A. is supported by a VENI grant of the Netherlands
Organisation for Scientific Research (NWO) (016.135.023)
and an AXA Research Fund fellowship. M.v.H. is sup-
ported by a Donders Institute Top Talent grant. B.F.’s
research is supported by grants by NWO Brain and
Cognition (443-09-223) and VICI (016.130.669), the EU
FP7 grants Aggressotype (602805) and IMAGEMEND
(602450), and the Hersenstichting Nederland. J.B. is
supported by NWO Large Investment Grant
(1750102007010), NWO Brain and Cognition grants
(433-09-242 and 056-13-015), and the EU FP7 grants
TACTICS (278948), Aggressotype (602805) and
IMAGEMEND (602450) and J.B. has been a consultant
in the past 3 years to/member of advisory board of and/or
speaker for Janssen Cilag BV, Eli Lilly and Servier, but he
is not an employee or a stock shareholder. R.C. was
supported by a VIDI grant of NWO (016095340), and
currently holds a James McDonnell Scholar award. R.C. is
a consultant to Abbott Laboratories and Pfizer, but she is
not an employee or a stock shareholder. For the remaining
authors there are no conflicts of interest.
References
Aarts E, Roelofs A, Franke B, Rijpkema M, Fernández G, Helmich RC, Cools R
(2010). Striatal dopamine mediates the interface between motivational
and cognitive control in humans: evidence from genetic imaging.
Neuropsychopharmacology 35:1943–1951.
Aarts E, van Holstein M, Cools R (2011). Striatal dopamine and the interface
between motivation and cognition. Front Psychol 2:163.
Aarts E, Helmich RC, Janssen MJ, Oyen WJ, Bloem BR, Cools R (2012). Aberrant
reward processing in Parkinson's disease is associated with dopamine
cell loss. Neuroimage 59:3339–3346.
Aarts E, Nusselein AA, Smittenaar P, Helmich RC, Bloem BR, Cools R (2014a).
Greater striatal responses to medication in Parkinson’s disease are asso-
ciated with better task-switching but worse reward performance.
Neuropsychologia 62:390–397.
Aarts E, Wallace DL, Dang LC, Jagust WJ, Cools R, D'Esposito M (2014b).
Dopamine and the cognitive downside of a promised bonus. Psychol Sci
25:1003–1009.
American Psychiatric Association (1994). Diagnostic and Statistical Manual of
Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing.
American Psychiatric Association (2013). Diagnostic and Statistical Manual of
Mental Disorders. 5th ed. Arlington, VA: American Psychiatric Publishing.
Arnsten AF, Li BM (2005). Neurobiology of executive functions: catecholamine
influences on prefrontal cortical functions. Biol Psychiatry 57:1377–1384.
Aron AR, Dowson JH, Sahakian BJ, Robbins TW (2003). Methylphenidate
improves response inhibition in adults with attention-deficit/hyperactivity dis-
order. Biol Psychiatry 54:1465–1468.
Ashburner J, Friston KJ (2005). Unified segmentation. Neuroimage 26:839–851.
Barkley RA (1997). Behavioral inhibition, sustained attention, and executive
functions: constructing a unifying theory of ADHD. Psychol Bull 121:65–94.
Bédard AC, Schulz KP, Cook EH Jr, Fan J, Clerkin SM, Ivanov I, et al. (2010).
Dopamine transporter gene variation modulates activation of striatum in youth
with ADHD. Neuroimage 53:935–942.
Berridge CW, Devilbiss DM, Andrzejewski ME, Arnsten AF, Kelley AE,
Schmeichel B, et al. (2006). Methylphenidate preferentially increases cate-
cholamine neurotransmission within the prefrontal cortex at low doses that
enhance cognitive function. Biol Psychiatry 60:1111–1120.
Bilder RM, Volavka J, Lachman HM, Grace AA (2004). The catechol-O-
methyltransferase polymorphism: relations to the tonic-phasic dopamine
238 Behavioural Pharmacology 2015, Vol 26 No 1&2
hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacology
29:1943–1961.
Bond AJ, Lader MH (1974). The use of analogue scales in rating subjective
feelings. Br J Med Psychol 47:211 – 218.
Brookes KJ, Xu X, Anney R, Franke B, Zhou K, Chen W, et al. (2008). Association
of ADHD with genetic variants in the 5′-region of the dopamine transporter
gene: evidence for allelic heterogeneity. Am J Med Genet B Neuropsychiatr
Genet 147B:1519–1523.
Bush G, Frazier JA, Rauch SL, Seidman LJ, Whalen PJ, Jenike MA, et al. (1999).
Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder
revealed by fMRI and the Counting Stroop. Biol Psychiatry 45:1542–1552.
Button KS, Ioannidis JP, Mokrysz C, Nosek BA, Flint J, Robinson ES, Munafò MR
(2013). Power failure: why small sample size undermines the reliability of
neuroscience. Nat Rev Neurosci 14:365–376.
Carmona S, Hoekzema E, Ramos-Quiroga JA, Richarte V, Canals C, Bosch R,
et al. (2012). Response inhibition and reward anticipation in medication-naïve
adults with attention-deficit/hyperactivity disorder: a within-subject case-
control neuroimaging study. Hum Brain Mapp 33:2350–2361.
Ciliax BJ, Drash GW, Staley JK, Haber S, Mobley CJ, Miller GW, et al. (1999).
Immunocytochemical localization of the dopamine transporter in human brain.
J Comp Neurol 409:38–56.
Clatworthy PL, Lewis SJ, Brichard L, Hong YT, Izquierdo D, Clark L, et al. (2009).
Dopamine release in dissociable striatal subregions predicts the different
effects of oral methylphenidate on reversal learning and spatial working
memory. J Neurosci 29:4690–4696.
Colzato LS, van den Wildenberg WP, Van der Does AJ, Hommel B (2010).
Genetic markers of striatal dopamine predict individual differences in dys-
functional, but not functional impulsivity. Neuroscience 170:782–788.
Cools AR (1980). Role of the neostriatal dopaminergic activity in sequencing and
selecting behavioural strategies: facilitation of processes involved in selecting
the best strategy in a stressful situation. Behav Brain Res 1:361–378.
Cools R, D'Esposito M (2011). Inverted-U-shaped dopamine actions on human
working memory and cognitive control. Biol Psychiatry 69:e113–e125.
Cools AR, van den Bercken JH, Horstink MW, van Spaendonck KP, Berger HJ
(1984). Cognitive and motor shifting aptitude disorder in Parkinson's disease.
J Neurol Neurosurg Psychiatry 47:443–453.
Cortese S, Kelly C, Chabernaud C, Proal E, Di Martino A, Milham MP,
Castellanos FX (2012). Toward systems neuroscience of ADHD: a meta-
analysis of 55 fMRI studies. Am J Psychiatry 169:1038–1055.
Costa A, Riedel M, Müller U, Möller HJ, Ettinger U (2011). Relationship between
SLC6A3 genotype and striatal dopamine transporter availability: a meta-
analysis of human single photon emission computed tomography studies.
Synapse 65:998–1005.
Cubillo A, Halari R, Ecker C, Giampietro V, Taylor E, Rubia K (2010). Reduced
activation and inter-regional functional connectivity of fronto-striatal networks
in adults with childhood Attention-Deficit Hyperactivity Disorder (ADHD) and
persisting symptoms during tasks of motor inhibition and cognitive switching.
J Psychiatr Res 44:629–639.
Desman C, Petermann F, Hampel P (2008). Deficit in response inhibition in
children with attention deficit/hyperactivity disorder (ADHD): impact of moti-
vation? Child Neuropsychol 14:483–503.
De Zeeuw P, Weusten J, van Dijk S, van Belle J, Durston S (2012). Deficits in
cognitive control, timing and reward sensitivity appear to be dissociable
in ADHD. PLoS One 7:e51416.
Dibbets P, Evers EA, Hurks PP, Bakker K, Jolles J (2010). Differential brain acti-
vation patterns in adult attention-deficit hyperactivity disorder (ADHD) asso-
ciated with task switching. Neuropsychology 24:413–423.
Dickstein SG, Bannon K, Castellanos FX, Milham MP (2006). The neural corre-
lates of attention deficit hyperactivity disorder: an ALE meta-analysis. J Child
Psychol Psychiatry 47:1051–1062.
Dodds CM, Müller U, Clark L, van Loon A, Cools R, Robbins TW (2008).
Methylphenidate has differential effects on blood oxygenation level-dependent
signal related to cognitive subprocesses of reversal learning. J Neurosci
28:5976–5982.
Dreher JC, Kohn P, Kolachana B, Weinberger DR, Berman KF (2009). Variation in
dopamine genes influences responsivity of the human reward system. Proc
Natl Acad Sci U S A 106:617–622.
Durston S, Fossella JA, Mulder MJ, Casey BJ, Ziermans TB, Vessaz MN, Van
Engeland H (2008). Dopamine transporter genotype conveys familial risk of
attention-deficit/hyperactivity disorder through striatal activation. J Am Acad
Child Adolesc Psychiatry 47:61–67.
Durston S, de Zeeuw P, Staal WG (2009). Imaging genetics in ADHD: a focus on
cognitive control. Neurosci Biobehav Rev 33:674–689.
Durston S, van Belle J, de Zeeuw P (2011). Differentiating frontostriatal and
fronto-cerebellar circuits in attention-deficit/hyperactivity disorder. Biol
Psychiatry 69:1178–1184.
Epstein JN, Casey BJ, Tonev ST, Davidson MC, Reiss AL, Garrett A, et al. (2007).
ADHD- and medication-related brain activation effects in concordantly
affected parent-child dyads with ADHD. J Child Psychol Psychiatry
48:899–913.
Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P
(2005). Molecular genetics of attention-deficit/hyperactivity disorder. Biol
Psychiatry 57:1313–1323.
Faraone SV, Spencer TJ, Madras BK, Zhang-James Y, Biederman J (2014).
Functional effects of dopamine transporter gene genotypes on in vivo dopa-
mine transporter functioning: a meta-analysis. Mol Psychiatry 19:880–889.
Forbes EE, Brown SM, Kimak M, Ferrell RE, Manuck SB, Hariri AR (2009).
Genetic variation in components of dopamine neurotransmission impacts
ventral striatal reactivity associated with impulsivity. Mol Psychiatry 14:60–70.
Franke B, Hoogman M, Arias Vasquez A, Heister JG, Savelkoul PJ, Naber M, et al.
(2008). Association of the dopamine transporter (SLC6A3/DAT1) gene 9-6
haplotype with adult ADHD. Am J Med Genet B Neuropsychiatr Genet
147B:1576–1579.
Franke B, Vasquez AA, Johansson S, Hoogman M, Romanos J, Boreatti-
Hümmer A, et al. (2010). Multicenter analysis of the SLC6A3/DAT1 VNTR
haplotype in persistent ADHD suggests differential involvement of the gene in
childhood and persistent ADHD. Neuropsychopharmacology 35:656–664.
Furukawa E, Bado P, Tripp G, Mattos P, Wickens JR, Bramati IE, et al. (2014).
Abnormal striatal BOLD responses to reward anticipation and reward delivery
in ADHD. PLoS One 9:e89129.
Gainetdinov RR, Jones SR, Caron MG (1999). Functional hyperdopaminergia in
dopamine transporter knock-out mice. Biol Psychiatry 46:303–311.
Giros B, Jaber M, Jones SR, Wightman RM, Caron MG (1996). Hyperlocomotion
and indifference to cocaine and amphetamine in mice lacking the dopamine
transporter. Nature 379:606–612.
Gizer IR, Ficks C, Waldman ID (2009). Candidate gene studies of ADHD: a meta-
analytic review. Hum Genet 126:51–90.
Glow PH, Glow RA (1979). Hyperkinetic impulse disorder: a developmental
defect of motivation. Genet Psychol Monogr 100:159–231.
Grahn JA, Parkinson JA, Owen AM (2008). The cognitive functions of the caudate
nucleus. Prog Neurobiol 86:141–155.
Haber SN (2003). The primate basal ganglia: parallel and integrative networks.
J Chem Neuroanat 26:317–330.
Haber SN, Fudge JL, McFarland NR (2000). Striatonigrostriatal pathways in pri-
mates form an ascending spiral from the shell to the dorsolateral striatum.
J Neurosci 20:2369–2382.
Hoogman M, Aarts E, Zwiers M, Slaats-Willemse D, Naber M, Onnink M, et al.
(2011). Nitric oxide synthase genotype modulation of impulsivity and ventral
striatal activity in adult ADHD patients and healthy comparison subjects. Am J
Psychiatry 168:1099–1106.
Hoogman M, Onnink M, Cools R, Aarts E, Kan C, Arias Vasquez A, et al. (2013).
The dopamine transporter haplotype and reward-related striatal responses in
adult ADHD. Eur Neuropsychopharmacol 23:469–478.
Ikeda H, Saigusa T, Kamei J, Koshikawa N, Cools AR (2013). Spiraling dopami-
nergic circuitry from the ventral striatum to dorsal striatum is an effective feed-
forward loop. Neuroscience 241:126–134.
Kambeitz J, Romanos M, Ettinger U (2014). Meta-analysis of the association
between dopamine transporter genotype and response to methylphenidate
treatment in ADHD. Pharmacogenomics J 14:77–84.
Karalunas SL, Huang-Pollock CL (2011). Examining relationships between
executive functioning and delay aversion in attention deficit hyperactivity dis-
order. J Clin Child Adolesc Psychol 40:837–847.
Kessler RC, Adler L, Barkley R, Biederman J, Conners CK, Demler O, et al.
(2006). The prevalence and correlates of adult ADHD in the United States:
results from the National Comorbidity Survey Replication. Am J Psychiatry
163:716–723.
Konrad K, Gauggel S, Manz A, Schöll M (2000). Lack of inhibition: a motivational
deficit in children with attention deficit/hyperactivity disorder and children with
traumatic brain injury. Child Neuropsychol 6:286–296.
Kooij JJ, Francken MH (2007). Diagnostisch Interview Voor ADHD (DIVA) bij
volwassenen. Available at: http://www.psyq.nl/Programma/Kenniscentrum-
ADHD-bij-volwassenen/diagnostiek-en-protocollen-adhd [Accessed 12
November 2014].
Kooij JJ, Buitelaar JK, van den Oord EJ, Furer JW, Rijnders CA, Hodiamont PP
(2005). Internal and external validity of attention-deficit hyperactivity disorder
in a population-based sample of adults. Psychol Med 35:817–827.
Lewis R, Kupke T (1977). The Lafayette clinic repeatable neuropsychological test
battery. Its development and research applications. Hollywood, FL:
Southeastern Psychological Association.
Majdandzić J, Grol MJ, van Schie HT, Verhagen L, Toni I, Bekkering H (2007). The
role of immediate and final goals in action planning: an fMRI study.
Neuroimage 37:589–598.
Striatal dopamine and cognition in adult ADHD Aarts et al. 239
McCarthy H, Skokauskas N, Frodl T (2014). Identifying a consistent pattern of
neural function in attention deficit hyperactivity disorder: a meta-analysis.
Psychol Med 44:869–880.
Munafò MR, Gage SH (2013). Improving the reliability and reporting of genetic
association studies. Drug Alcohol Depend 132:411–413.
Onnink AM, Zwiers MP, Hoogman M, Mostert JC, Kan CC, Buitelaar J, Franke B
(2014). Brain alterations in adult ADHD: effects of gender, treatment and
comorbid depression. Eur Neuropsychopharmacol 24:397–409.
Oosterlaan J, Sergeant JA (1998). Effects of reward and response cost on
response inhibition in AD/HD, disruptive, anxious, and normal children.
J Abnorm Child Psychol 26:161–174.
Paloyelis Y, Mehta MA, Faraone SV, Asherson P, Kuntsi J (2012). Striatal sensi-
tivity during reward processing in attention-deficit/hyperactivity disorder. J Am
Acad Child Adolesc Psychiatry 51:722–732, e729.
Patton JH, Stanford MS, Barratt ES (1995). Factor structure of the Barratt
impulsiveness scale. J Clin Psychol 51:768–774.
Plichta MM, Scheres A (2014). Ventral-striatal responsiveness during reward
anticipation in ADHD and its relation to trait impulsivity in the healthy popu-
lation: a meta-analytic review of the fMRI literature. Neurosci Biobehav Rev
38:125–134.
Plichta MM, Vasic N, Wolf RC, Lesch KP, Brummer D, Jacob C, et al. (2009).
Neural hyporesponsiveness and hyperresponsiveness during immediate and
delayed reward processing in adult attention-deficit/hyperactivity disorder.
Biol Psychiatry 65:7–14.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA (2007). The
worldwide prevalence of ADHD: a systematic review and metaregression
analysis. Am J Psychiatry 164:942–948.
Reeves S, Bench C, Howard R (2002). Ageing and the nigrostriatal dopaminergic
system. Int J Geriatr Psychiatry 17:359–370.
Rokem A, Landau AN, Prinzmetal W, Wallace DL, Silver MA, D'Esposito M
(2012). Modulation of inhibition of return by the dopamine D2 receptor ago-
nist bromocriptine depends on individual DAT1 genotype. Cereb Cortex
22:1133–1138.
Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E (2009).
Methylphenidate normalises activation and functional connectivity deficits in
attention and motivation networks in medication-naïve children with ADHD
during a rewarded continuous performance task. Neuropharmacology
57:640–652.
Rubia K, Halari R, Cubillo A, Smith AB, Mohammad AM, Brammer M, Taylor E
(2011). Methylphenidate normalizes fronto-striatal underactivation during
interference inhibition in medication-naïve boys with attention-deficit hyper-
activity disorder. Neuropsychopharmacology 36:1575–1586.
Salthouse TA (1996). The processing-speed theory of adult age differences in
cognition. Psychol Rev 103:403–428.
Scheres A, Milham MP, Knutson B, Castellanos FX (2007). Ventral striatal
hyporesponsiveness during reward anticipation in attention-deficit/hyper-
activity disorder. Biol Psychiatry 61:720–724.
Schmeichel BE, Zemlan FP, Berridge CW (2013). A selective dopamine reuptake
inhibitor improves prefrontal cortex-dependent cognitive function: potential
relevance to attention deficit hyperactivity disorder. Neuropharmacology
64:321–328.
Sergeant JA, Geurts H, Huijbregts S, Scheres A, Oosterlaan J (2003). The top
and the bottom of ADHD: a neuropsychological perspective. Neurosci
Biobehav Rev 27:583–592.
Shafritz KM, Marchione KE, Gore JC, Shaywitz SE, Shaywitz BA (2004). The
effects of methylphenidate on neural systems of attention in attention deficit
hyperactivity disorder. Am J Psychiatry 161:1990–1997.
Shanahan MA, Pennington BF, Willcutt EW (2008). Do motivational incentives
reduce the inhibition deficit in ADHD? Dev Neuropsychol 33:137–159.
Sheskin DJ (2004). Handbook of parametric and non-parametric statistical
procedures. 3rd ed. Boca Raton, Florida: Chapman and Hall/CRC Press.
Simon V, Czobor P, Bálint S, Mészáros A, Bitter I (2009). Prevalence and cor-
relates of adult attention-deficit hyperactivity disorder: meta-analysis. Br J
Psychiatry 194:204–211.
Slusarek M, Velling S, Bunk D, Eggers C (2001). Motivational effects on inhibitory
control in children with ADHD. J Am Acad Child Adolesc Psychiatry
40:355–363.
Sonuga-Barke EJ (2002). Psychological heterogeneity in AD/HD – a dual path-
way model of behaviour and cognition. Behav Brain Res 130:29–36.
Sonuga-Barke EJ (2003). The dual pathway model of AD/HD: an elaboration of
neuro-developmental characteristics. Neurosci Biobehav Rev 27:593–604.
Sonuga-Barke EJ (2005). Causal models of attention-deficit/hyperactivity dis-
order: from common simple deficits to multiple developmental pathways. Biol
Psychiatry 57:1231–1238.
Spreen FO, Benton AL (1977). Manual of Instructions for the Neurosensory
Center Comprehensive Examination for Aphasia. VIC, British Columbia,
Canada: University of Victoria.
Ströhle A, Stoy M, Wrase J, Schwarzer S, Schlagenhauf F, Huss M, et al. (2008).
Reward anticipation and outcomes in adult males with attention-deficit/
hyperactivity disorder. Neuroimage 39:966–972.
Tomasi D, Volkow ND (2012). Abnormal functional connectivity in children with
attention-deficit/hyperactivity disorder. Biol Psychiatry 71:443–450.
Uebel H, Albrecht B, Asherson P, Börger NA, Butler L, Chen W, et al. (2010).
Performance variability, impulsivity errors and the impact of incentives as
gender-independent endophenotypes for ADHD. J Child Psychol Psychiatry
51:210–218.
Vaidya CJ, Austin G, Kirkorian G, Ridlehuber HW, Desmond JE, Glover GH,
Gabrieli JD (1998). Selective effects of methylphenidate in attention deficit
hyperactivity disorder: a functional magnetic resonance study. Proc Natl Acad
Sci U S A 95:14494–14499.
Van Holstein M, Aarts E, van der Schaaf ME, Geurts DE, Verkes RJ, Franke B,
et al. (2011). Human cognitive flexibility depends on dopamine D2 receptor
signaling. Psychopharmacology (Berl) 218:567–578.
Verhagen L, Dijkerman HC, Grol MJ, Toni I (2008). Perceptuo-motor interactions
during prehension movements. J Neurosci 28:4726–4735.
Verheij MM, Cools AR (2008). Twenty years of dopamine research: individual
differences in the response of accumbal dopamine to environmental and
pharmacological challenges. Eur J Pharmacol 585:228–244.
Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. (1995). A
new PET ligand for the dopamine transporter: studies in the human brain.
J Nucl Med 36:2162–2168.
Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. (1996).
Dopamine transporters decrease with age. J Nucl Med 37:554–559.
Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, et al. (1998).
Dopamine transporter occupancies in the human brain induced by therapeutic
doses of oral methylphenidate. Am J Psychiatry 155:1325–1331.
Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ (2002). Mechanism of action
of methylphenidate: insights from PET imaging studies. J Atten Disord 6
Suppl 1:S31–S43.
Volkow ND, Wang GJ, Kollins SH, Wigal TL, Newcorn JH, Telang F, et al. (2009).
Evaluating dopamine reward pathway in ADHD: clinical implications. JAMA
302:1084–1091.
Volkow ND, Wang GJ, Tomasi D, Kollins SH, Wigal TL, Newcorn JH, et al. (2012).
Methylphenidate-elicited dopamine increases in ventral striatum are asso-
ciated with long-term symptom improvement in adults with attention deficit
hyperactivity disorder. J Neurosci 32:841–849.
240 Behavioural Pharmacology 2015, Vol 26 No 1&2
